FDA Reauthorizes Philip Morris' IQOS as Modified Risk Tobacco Product
Event summary
- The FDA renewed MRTP authorizations for Philip Morris' IQOS devices and HEETS consumables on April 17, 2026.
- Renewal covers IQOS 2.4 and 3.0 systems along with three HEETS variants (Amber, Green Menthol, Blue Menthol).
- FDA cited substantial reduction in harmful chemicals compared to cigarette smoke as key rationale.
- PMI aims to convert 25 million U.S. adult smokers from combustible cigarettes to smoke-free alternatives.
The big picture
This reauthorization solidifies Philip Morris' position as the only company with MRTP authorizations for heated tobacco products in the U.S. The decision comes as part of a broader industry shift toward harm reduction, with PMI investing $16 billion since 2008 to develop smoke-free alternatives. The company's acquisition of Swedish Match in 2022 further strengthened its portfolio in oral nicotine delivery, positioning it as a global leader in the transition away from combustible cigarettes.
What we're watching
- Regulatory Dynamics
- How FDA's expedited review of IQOS ILUMA application will impact PMI's U.S. market expansion.
- Market Penetration
- The pace at which heated tobacco products reduce combustible cigarette consumption in the U.S.
- Competitive Positioning
- Whether PMI can sustain its leadership in smoke-free alternatives amid growing competition.
Related topics